| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 02/15/2001 | DE19936719A1 Substituierte 1,5-Dihydropyrrol-2-on-Derivate Substituted 1,5-dihydropyrrol-2-one derivatives |
| 02/15/2001 | DE19936521A1 Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate Substituted pyrrolidine-2,3,4-trione-3-oxime Derivatives |
| 02/15/2001 | CA2381910A1 Novel vitamin d analogues |
| 02/15/2001 | CA2381621A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 02/15/2001 | CA2381284A1 Fhm, a novel member of the tnf ligand supergene family |
| 02/15/2001 | CA2381215A1 P38map kinase inhibitors |
| 02/15/2001 | CA2381033A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | CA2380973A1 Substituted pyrrolidine-2-3,4-trione 3-oxime derivatives which are active as nmda receptor antagonists |
| 02/15/2001 | CA2380678A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | CA2379977A1 Novel integrin receptor antagonists |
| 02/15/2001 | CA2379052A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | CA2378990A1 1,4-substituted 4,4-diaryl cyclohexanes |
| 02/15/2001 | CA2378499A1 Cyclic amine ccr3 antagonists |
| 02/15/2001 | CA2378480A1 Pharmaceutical compositions containing tripeptides |
| 02/15/2001 | CA2378401A1 Implantable active ingredient depot |
| 02/15/2001 | CA2378310A1 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 02/15/2001 | CA2378285A1 Vaccines for the treatment of autoimmune disease |
| 02/15/2001 | CA2377422A1 Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof |
| 02/14/2001 | EP1075840A2 Therapeutic and prophylactic uses of antithrombin III |
| 02/14/2001 | EP1075528A1 Endothelin-converting-enzyme like protein |
| 02/14/2001 | EP1075519A2 Inhibitors of nf-kb activation |
| 02/14/2001 | EP1075496A1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis |
| 02/14/2001 | EP1075493A2 Dna encoding snorf25 receptor |
| 02/14/2001 | EP1075492A1 Melanocortin 1 receptor selective compounds |
| 02/14/2001 | EP1075489A2 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues |
| 02/14/2001 | EP1075476A1 Novel benzimidazoles and benzoxazoles |
| 02/14/2001 | EP1075475A1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production |
| 02/14/2001 | EP1075472A1 Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists |
| 02/14/2001 | EP1075467A1 Pyrazole derivatives as p-38 map kinase inhibitors |
| 02/14/2001 | EP1075277A2 Methods for detecting and inhibiting angiogenesis |
| 02/14/2001 | EP1075256A1 Arylhydrocarbon receptor ligand antagonists |
| 02/14/2001 | EP1075254A2 The use of polyamines in the treatment of dermatological symptoms |
| 02/14/2001 | EP0968226A4 G-rich oligo aptamers and methods of modulating an immune response |
| 02/14/2001 | EP0844874A4 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS |
| 02/14/2001 | CN1284134A Methods of producing anti-angiogenic proteins: endostation, angiostation or restin, using pichia yeast expression system |
| 02/14/2001 | CN1284130A Mutants of endostation, 'EM1' having ant-angiogenic activety and methods of use thereof |
| 02/14/2001 | CN1284077A Purine derivatives having phosphodiesterase IV inhibition activity |
| 02/14/2001 | CN1284073A 5-(2-imidazolinylamino)-benzimidazole derivatives, their prepn. and their use as alpha-adrenoceptor agonists with inproved metabolic stability |
| 02/14/2001 | CN1284064A 2,3-substituted indole compounds as cox-2 inhibitors |
| 02/14/2001 | CN1284057A Adamantane derivatives |
| 02/14/2001 | CN1061870C Medicated wine for sauna bath |
| 02/13/2001 | US6187930 Reacting selected amine with optically active acid selected from (+)-ditoluyl-l-tartaric acid and/or (-)-ditoluyl-l-tartaric acid in solvent to form diasteroisomeric salt, separating, isolating enantiomer |
| 02/13/2001 | US6187810 Administering to improve the therapeutic effect and the bioavailability of known medicaments; administering to diminish acute or chronic toxicity of a natural alkaloid, cardiac glycoside or synthetic drug |
| 02/13/2001 | US6187803 Treating allergic disease, autoimmune disease, immunodeficiency syndrome, inflammatory disease or eosinophilia by orally administering a histamine-added immunoglobulin and carrier; tablets, capsules |
| 02/13/2001 | US6187792 Compounds with analgesic effect |
| 02/13/2001 | US6187777 Pyrrolo(3,2-d)pyrimidine derivatives; neuropeptide y and corticotropin releasing factor modulators; dietetics; antidiabetic, antiinflammatory, and antitumor agents |
| 02/13/2001 | US6187771 Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
| 02/13/2001 | US6187770 N-substituted azaheterocyclic compounds |
| 02/13/2001 | CA2315588A1 Use of antithrombin iii for the prophylaxis and therapy of diseases |
| 02/13/2001 | CA2170065C Amide-derived bi-aromatic compounds; pharmaceutical and cosmetic compositions containing the same and their uses |
| 02/13/2001 | CA2146637C Pharmaceutical compositions and methods for treating cold symptoms |
| 02/13/2001 | CA2048619C Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat lipopolysaccharide associated gram negative infections |
| 02/13/2001 | CA2021788C Cyclosporin derivatives |
| 02/12/2001 | CA2280249A1 Vanadium compounds as anti-angiogenics and as inhibitors of endothelin production |
| 02/08/2001 | WO2001055118A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient |
| 02/08/2001 | WO2001009350A2 Genetically engineered bleb vaccine |
| 02/08/2001 | WO2001009328A1 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof |
| 02/08/2001 | WO2001009182A1 Prolactin-releasing peptide and method for regulating autonomic functions and treating pain |
| 02/08/2001 | WO2001009178A2 Human chaperone proteins |
| 02/08/2001 | WO2001009173A2 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 02/08/2001 | WO2001009159A1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins |
| 02/08/2001 | WO2001009138A2 Chemokine receptor antagonists and methods of use therefor |
| 02/08/2001 | WO2001009134A1 Purine derivatives inhibitors of tyrosine protein kinase syk |
| 02/08/2001 | WO2001009130A1 TRICYCLIC COMPOUNDS HAVING sPLA2-INHIBITORY ACTIVITIES |
| 02/08/2001 | WO2001009121A2 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 02/08/2001 | WO2001009119A2 Chemokine receptor antagonists |
| 02/08/2001 | WO2001009097A1 Cyclic amine derivatives for the treatment of neurological diseases |
| 02/08/2001 | WO2001009094A2 Chemokine receptor antagonists and methods of use therefor |
| 02/08/2001 | WO2001009090A2 Hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |
| 02/08/2001 | WO2001008717A1 Controlled release implantable devices |
| 02/08/2001 | WO2001008699A1 Methods of inhibiting osteoclastogenesis |
| 02/08/2001 | WO2001008689A1 Ophthalmic compositions containing antibiotics and nsaids |
| 02/08/2001 | WO2001008685A1 Acyclic and cyclic amine derivatives |
| 02/08/2001 | WO2001008684A1 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 02/08/2001 | WO2001008682A2 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 02/08/2001 | WO2001008677A1 Methods of inhibiting osteoclast activity |
| 02/08/2001 | WO2001008674A1 Sulfonamide derivatives and remedies for allodynia |
| 02/08/2001 | WO2001008673A1 Calcilytic compounds |
| 02/08/2001 | WO2001008657A2 Personal care articles |
| 02/08/2001 | WO2001008634A2 Polynucleotide encoding a human serine protease |
| 02/08/2001 | WO2000067769A8 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents |
| 02/08/2001 | WO2000064485A8 Specifically targeted catalytic antagonists and uses thereof |
| 02/08/2001 | WO2000058307A3 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 02/08/2001 | WO2000058295A3 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 02/08/2001 | WO2000054758A3 Method for delivering benzidine prostaglandins by inhalation |
| 02/08/2001 | DE10037121A1 Antipyretic composition for treating intensively reared animals, comprising stable, concentrated paracetamol solution in polyethylene glycol and/or polypropylene glycol, added to drinking water or sprayed on feed |
| 02/08/2001 | CA2820314A1 Vaccine composition |
| 02/08/2001 | CA2820271A1 Vaccine composition |
| 02/08/2001 | CA2647796A1 Method of inhibiting osteoclast activity |
| 02/08/2001 | CA2391267A1 Chemokine receptor antagonists and methods of use therefor |
| 02/08/2001 | CA2388663A1 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 02/08/2001 | CA2388297A1 Ophthalmic compositions containing antibiotics and nsaids |
| 02/08/2001 | CA2381004A1 Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins |
| 02/08/2001 | CA2380840A1 Vaccine composition |
| 02/08/2001 | CA2380644A1 2-pyrazolin-5-ones |
| 02/08/2001 | CA2380573A1 Prolactin-releasing peptide and method for regulating autonomic functions and treating pain |
| 02/08/2001 | CA2380111A1 Controlled release implantable devices |
| 02/08/2001 | CA2380081A1 Calcilytic compounds |
| 02/08/2001 | CA2380009A1 Methods of inhibiting osteoclastogenesis |
| 02/08/2001 | CA2380007A1 Methods of inhibiting osteoclast activity |